+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID04217733

Comparing Ethosuximide and Pentoxifylline to Mebeverine for Treating Abdominal Pain in Irritable Bowel Syndrome

Led by Tanta University · Updated on 2020-01-03

60

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the safety and effectiveness of two drugs, ethosuximide and pentoxifylline, for treating abdominal pain related to irritable bowel syndrome IBS. It compares these treatments to a current medication, mebeverine, to see if they provide additional relief. The study is a phase 3 clinical trial conducted with adult men and women diagnosed with IBS according to Rome criteria IV who experience moderate to severe pain. Participants are randomly assigned to one of three groups receiving either mebeverine three times daily, ethosuximide three times daily, or pentoxifylline twice daily, each for a period of three months. The trial uses a triple-blind design to monitor and compare the effects of these drugs on IBS-related abdominal pain. During the study, patients will be regularly assessed for changes in pain using the Visual Analog Scale VAS, with researchers tracking improvements over six months. Safety and any side effects are also monitored. The overall goal is to understand if ethosuximide or pentoxifylline can add benefit to existing IBS treatments under stable conditions.

CONDITIONS

Brief Title

Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome

Research Team

S

Sherief Abd-Elsalam, ass. prof.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here